184 related articles for article (PubMed ID: 19092656)
1. Clot lifespan model analysis of the effects of warfarin on thrombus growth and fibrinolysis: role of contact protein and tissue factor initiation.
Nielsen VG; Kirklin JK; Holman WL; Steenwyk BL
ASAIO J; 2009; 55(1):33-40. PubMed ID: 19092656
[TBL] [Abstract][Full Text] [Related]
2. Carbon monoxide releasing molecule-2 enhances coagulation and diminishes fibrinolytic vulnerability in subjects exposed to warfarin.
Nielsen VG; Khan ES; Kirklin JK; George JF
Thromb Res; 2010 Jul; 126(1):68-73. PubMed ID: 20406708
[TBL] [Abstract][Full Text] [Related]
3. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII.
Nielsen VG; Steenwyk BL; Gurley WQ
J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938
[TBL] [Abstract][Full Text] [Related]
4. Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation.
Nielsen VG
Ann Thorac Surg; 2006 May; 81(5):1720-7. PubMed ID: 16631662
[TBL] [Abstract][Full Text] [Related]
5. Corn trypsin inhibitor decreases tissue-type plasminogen activator-mediated fibrinolysis of human plasma.
Nielsen VG
Blood Coagul Fibrinolysis; 2009 Apr; 20(3):191-6. PubMed ID: 19657316
[TBL] [Abstract][Full Text] [Related]
6. Relationship between chromogenic factor X and international normalized ratio differs during early warfarin initiation compared with chronic warfarin administration.
Rosborough TK; Jacobsen JM; Shepherd MF
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):433-5. PubMed ID: 19543077
[TBL] [Abstract][Full Text] [Related]
7. Hemodilution modulates the time of onset and rate of fibrinolysis in human and rabbit plasma.
Nielsen VG
J Heart Lung Transplant; 2006 Nov; 25(11):1344-52. PubMed ID: 17097499
[TBL] [Abstract][Full Text] [Related]
8. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation.
Nielsen VG; Cohen BM; Cohen E
Blood Coagul Fibrinolysis; 2006 Jan; 17(1):75-81. PubMed ID: 16607085
[TBL] [Abstract][Full Text] [Related]
9. Clot life span model analysis of clot growth and fibrinolysis in normal subjects: role of thrombin activatable fibrinolysis inhibitor.
Nielsen VG
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):283-7. PubMed ID: 18469549
[TBL] [Abstract][Full Text] [Related]
10. Epsilon-aminocaproic acid inhibition of fibrinolysis in vitro: should the 'therapeutic' concentration be reconsidered?
Nielsen VG; Cankovic L; Steenwyk BL
Blood Coagul Fibrinolysis; 2007 Jan; 18(1):35-9. PubMed ID: 17179824
[TBL] [Abstract][Full Text] [Related]
11. Point-of-care monitoring of oral anticoagulation therapy in children. Comparison of the CoaguChek XS system with venous INR and venous INR using an International Reference Thromboplastin preparation (rTF/95).
Greenway A; Ignjatovic V; Summerhayes R; Newall F; Burgess J; DeRosa L; Monagle P
Thromb Haemost; 2009 Jul; 102(1):159-65. PubMed ID: 19572081
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyethyl starch enhances fibrinolysis in human plasma by diminishing alpha2-antiplasmin-plasmin interactions.
Nielsen VG
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):647-56. PubMed ID: 17890952
[TBL] [Abstract][Full Text] [Related]
13. Oral anticoagulant initiation: rationale for the use of warfarin dosing nomograms.
Crowther MA
Semin Vasc Med; 2003 Aug; 3(3):255-60. PubMed ID: 15199458
[TBL] [Abstract][Full Text] [Related]
14. Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma.
Nielsen VG; Kirklin JK; George JF
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):448-55. PubMed ID: 19581800
[TBL] [Abstract][Full Text] [Related]
15. Effect of renal function on whole blood and fibrin clot formation in atrial fibrillation patients on warfarin.
Lau YC; Xiong Q; Lip GY; Blann AD
Ann Med; 2016; 48(4):275-81. PubMed ID: 27043881
[TBL] [Abstract][Full Text] [Related]
16. Carbon monoxide releasing molecule-2 attenuates the anticoagulant and amplifies the hypofibrinolytic effects of hypothermia in human plasma in vitro.
Nielsen VG; George SJ
Blood Coagul Fibrinolysis; 2011 Jan; 22(1):67-72. PubMed ID: 21157299
[TBL] [Abstract][Full Text] [Related]
17. Beyond cell based models of coagulation: analyses of coagulation with clot "lifespan" resistance-time relationships.
Nielsen VG
Thromb Res; 2008; 122(2):145-52. PubMed ID: 17935760
[TBL] [Abstract][Full Text] [Related]
18. Carbon monoxide releasing molecule-2 enhances coagulation and diminishes fibrinolytic vulnerability in plasma exposed to heparin or argatroban.
Nielsen VG; Khan ES; Kirklin JK; George JF
Anesth Analg; 2010 Dec; 111(6):1347-52. PubMed ID: 21048101
[TBL] [Abstract][Full Text] [Related]
19. Warfarin monitoring independent of the international normalized ratio (INR): a pilot study.
Carroll WE; Jackson RD
Res Commun Mol Pathol Pharmacol; 1997 Feb; 95(2):169-78. PubMed ID: 9090753
[TBL] [Abstract][Full Text] [Related]
20. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII.
Nielsen VG; Cohen BM; Cohen E
Acta Anaesthesiol Scand; 2005 Feb; 49(2):222-31. PubMed ID: 15715625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
